TB Alliance-Lupin Deal To Improve Pretomanid Access But India Unlikely To Benefit For Now

Viatris Has Capacity To Meet Demand

While Viatris says it has sufficient capacity to meet current and future demand for tuberculosis drug pretomanid, TB Alliance has signed a non-exclusive license with Lupin. This is the second tie-up with an Indian manufacturer but the local restricted use approval means countries other than India are likely to benefit for now.

Tuberculosis concept with the word written on paper
TB Is The Most Common Lethal Infectious Disease Globally • Source: Alamy

More from Business

More from Scrip